AUTHORS
Rodrigo P. Silva-Aguiar, PhD, Ernest R. Chan, PhD2, Alessandro S. Pinheiro, PhD3, Alona A. Merkulova4, Karina I. Carvalho, PhD5, Meghan Kapp, MD6, John Sedor, MD7, Ana Acacia S. Pinheiro, PhD8, Celso Caruso-Neves, PhD9, Jeffrey R. Schelling, MD10, Alvin H. Schmaier, MD11
AFFILIATIONS
1 Case Western Reserve University, Cleveland, United States
2 Case Western Reserve University, Cleveland, United States
3 Case Western Reserve University, Cleveland, United States
4 Case Western Reserve University, Cleveland, United States
5 Case Western Reserve University, Cleveland, United States
6 Case Western Reserve University, Cleveland, United States, University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
7 Case Western Reserve University, Cleveland, United States, Cleveland Clinic Foundation, Cleveland, United States
8 Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
9 Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
10 Case Western Reserve University, Cleveland, United States, University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
11 Case Western Reserve University, Cleveland, United States, University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
ABSTRACT
Chronic kidney disease (CKD) is an independent risk factor for cardiovascular events and all-cause mortality. Despite the huge social and economic impact, therapeutic options to prevent and treat CKD are limited by gaps in understanding its pathophysiology. Tubulointerstitial fibrosis (TIF) is a major determinant of renal functional decline in CKD, regardless of etiology. The precise mechanism(s) driving TIF, however, are unknown.
The contact activation pathway (CAP) of blood coagulation is an intravascular proteolytic system involved with hemostasis, thrombosis and inflammation. Activated factor XII (FXIIa) is the canonical central component of the CAP. However non-canonical activities of FXII, the zymogen, have been reported. FXII binds to urokinase plasminogen activator receptor (uPAR) to promote smooth muscle and endothelial cell growth, proliferation and angiogenesis and neutrophil adhesion, migration, chemotaxis, and NETosis. We hypothesized that FXII also participates in the development of renal fibrosis through canonical CAP or through non-canonical uPAR signaling.
Initially, we analyzed independent human renal RNA-Seq datasets from CKD patients. FXII (F12) and uPAR (PLAUR) renal gene expression were consistently increased in CKD samples and correlated with low glomerular filtration rates (GFR). These findings were not observed for FXII substrates FXI (F11), plasminogen (PLG) or prekallikrein (KLKB1). Common pathway components Factor X (F10) and prothrombin (F2) were also not associated with CKD. F12 gene expression correlated with renal tubule injury markers HAVCR1 and LCN2. Using the murine single folic acid (FA) injection model of renal fibrosis, increased serum creatinine (SCr), blood urea nitrogen (BUN) and extensive tubular injury and interstitial inflammation were observed in the FA-treated wild-type (WT) group compared to controls 4 weeks after injury. Two independent strains of FXII (F12-/-) deficient mice showed remarkable protection from changes in these parameters. Additionally, uPAR (Plaur-/-), but not the FXIIa substrate PK (Klkb1-/-) or FXIIa natural inhibitor C1INH (Serping1-/-) deficient mice, were protected from FA-induced CKD to the same extent as F12-/- mice. Furthermore, gene expression of other uPAR ligands, single chain urokinase plasminogen activator (scuPA) (PLAU) or vitronectin (VTN), were not associated with CKD in patients or mice, suggesting a specific FXII and uPAR mechanism in renal fibrosis development. No changes in plasma contact activation or contact-induced thrombin generation were observed when comparing FA-treated WT mice with controls. Renal immunofluorescence and immunoblotting, however, showed high FXII antigen level in proximal tubules from FA-treated WT mice compared to untreated mice. Bulk RNA-seq and gene set analysis showed an enrichment of Cytokine-Cytokine Receptor, Chemokine Signaling, Fibrosis and Senescence (SenMayo) pathways. There was no enrichment of any of those pathways in FA-treated F12-/- and Plaur-/- mice. Further, two independent cohorts of CKD patients confirmed that F12 and PLAUR gene expression correlated with fibrosis (COL1A1) and senescence (CDKN1A) markers. Mechanistically, WT-FA group showed marked enrichment of ERK1/2 pathway and increased phospho-ERK1/2 in fibrotic areas compared to controls, features completely absent in similarly treated F12-/- and Plaur-/- mice. Additionally, the fibrotic and senescent phenotypes were confirmed by 1) Masson trichrome staining, revealing extensive renal fibrosis in FA-treated WT but not F12-/- and Plaur-/- mice; and 2) Immunofluorescence staining and immunoblotting for γ-H2AX, a senescence marker, was increased in FA-treated WT but not in F12-/- and Plaur-/- mice.
In conclusion, these data indicated that non-canonical FXII/uPAR signaling promotes renal inflammation, fibrosis and senescence leading to CKD development after injury. Targeting the FXII/uPAR signaling pathway has potential to blunt the development of renal fibrosis after injury.
DISCLOSURES
Rodrigo P. Silva-Aguiar, PhD: No relevant conflicts of interest to declare.